Bluestem Buys Million VictoryShares Short-Term Bond ETF
BlueStem Wealth Partners disclosed a substantial new stake in VictoryShares Short-Term Bond ETF (USTB) during the lat...
Using index levels to time market involves aligning trades with key thresholds while avoiding over-interpretation of minor moves.
28,495 articlesBlueStem Wealth Partners disclosed a substantial new stake in VictoryShares Short-Term Bond ETF (USTB) during the lat...
A hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
Greg Abel, two months into his role as Berkshire Hathaway CEO, commits to using his after-tax salary to buy Berkshire...
A major move by hedge fund incline global to liquidate its Maplebear stake prompts a closer look at CART stock. Read ...
When a large hedge fund reduces its Celcuity stake, markets pay attention. This article breaks down the move, what it...
A new wave of policy proposals seeks to curb large landlords by banning institutional investors from buying single-fa...
Lucid stock has moved sharply lower, fueling debates about whether it’s a risky fall or a potential bargain. This gui...
Apple and Nvidia sit at the pinnacle of market caps, but they play very different roles in investors’ portfolios. Thi...
Could 2026 bring a surprise policy pivot? This guide explains why the Fed might hike instead of cutting, how that sce...
A lesser-known cloud platform is delivering eye-popping gains as AI demand climbs. Discover why this stock crushing N...
A major hedge fund just plowed a substantial stake into a gene-editing company, signaling conviction in Beam Therapeu...
When a stock climbs 15% after a fund trims its position, investors should look beyond the headline. This article brea...